MicroRNA‑21 serves an important role during PAOO‑facilitated orthodontic tooth movement.
microRNA‑21
periodontal accelerate osteogenesis orthodontics
tooth movement
osteoclasts
Journal
Molecular medicine reports
ISSN: 1791-3004
Titre abrégé: Mol Med Rep
Pays: Greece
ID NLM: 101475259
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
31
01
2020
accepted:
31
03
2020
pubmed:
8
5
2020
medline:
17
2
2021
entrez:
8
5
2020
Statut:
ppublish
Résumé
Periodontal accelerate osteogenesis orthodontics (PAOO) is an extension of described techniques that surgically alter the alveolar bone; however, the specific mechanism underlying the technique is not completely understood. The aim of the present study was to evaluate the roles of microRNA (miR)‑21 during PAOO. Sprague‑Dawley rats were divided into the following four groups: i) Group tooth movement (TM), underwent TM and were administered normal saline (NS); ii) Group PAOO, underwent PAOO + TM and were administered NS; iii) Group agomiR‑21, underwent PAOO + TM and were administered agomiR‑21; and iv) Group antagomiR‑21, underwent PAOO + TM and were administered antagomiR‑21. To validate the rat model of PAOO, morphological analyses were performed and measurements were collected. Reverse transcription‑quantitative PCR, western blotting and immunohistochemical staining were performed to examine the expression levels of programmed cell death 4 (PDCD4), activin A receptor type 2B (ACVR2b), receptor activator of NF‑κΒ ligand (RANKL) and C‑Fos. Dual‑luciferase reporter assays were performed to validate PDCD4 as a target of miR‑21 in vitro. Following 7 days of treatment, the TM distance of group PAOO was longer compared with groups TM and antagomiR‑21 (P<0.05), but shorter compared with group agomiR‑21 (P<0.05). Tartrate‑resistant acid phosphatase staining indicated that following treatment with agomiR‑21, osteoclast activity was notably increased, whereas the mRNA and protein expression levels of PDCD4 were notably decreased compared with group PAOO. The mRNA and protein expression levels of RANKL and C‑Fos in group agomiR‑21 were notably increased compared with group PAOO, whereas group antagomiR‑21 displayed the opposite pattern (P<0.05). With regard to ACVR2b, no significant differences were observed among the group agomiR‑21 and antagomiR‑21 compared with group PAOO. Bioinformatics analysis predicted that PDCD4 was a potential target gene of miR‑21, and dual‑luciferase reporter assays demonstrated that miR‑21 directly targeted PDCD4. In conclusion, the present study demonstrated that miR‑21 serves an important role during PAOO‑mediated orthodontic TM.
Identifiants
pubmed: 32377742
doi: 10.3892/mmr.2020.11107
pmc: PMC7248476
doi:
Substances chimiques
Apoptosis Regulatory Proteins
0
MicroRNAs
0
Pdcd4 protein, rat
0
mirn21 microRNA, rat
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
474-482Références
Genome Res. 2009 Jan;19(1):92-105
pubmed: 18955434
J Pharm Bioallied Sci. 2014 Jul;6(Suppl 1):S2-5
pubmed: 25210373
Stem Cells Int. 2017;2017:3028647
pubmed: 29213288
PLoS One. 2016 Aug 12;11(8):e0160803
pubmed: 27517874
J Dent Res. 2016 Nov;95(12):1425-1433
pubmed: 27422860
Oncogene. 2009 Jan 8;28(1):73-84
pubmed: 18850008
Connect Tissue Res. 2019 Sep;60(5):487-494
pubmed: 30909748
Nat Rev Genet. 2004 Jul;5(7):522-31
pubmed: 15211354
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
J Mol Biol. 2008 May 2;378(3):492-504
pubmed: 18384814
J Immunol. 2016 Dec 15;197(12):4639-4650
pubmed: 27849171
Medicine (Baltimore). 2018 Sep;97(37):e12047
pubmed: 30212935
Nat Rev Endocrinol. 2012 Jan 31;8(4):212-27
pubmed: 22290358
J Craniofac Surg. 2013;24(5):1750-2
pubmed: 24036771
Stem Cells Dev. 2015 Feb 1;24(3):312-9
pubmed: 25203845
Cell. 2003 Jun 13;113(6):685-700
pubmed: 12809600
Mol Endocrinol. 2012 Jan;26(1):87-94
pubmed: 22074949
Carcinogenesis. 2009 Jul;30(7):1209-16
pubmed: 19414503
Blood. 2011 Mar 31;117(13):3648-57
pubmed: 21273303
J Biol Chem. 2008 Jan 11;283(2):1026-33
pubmed: 17991735
Mol Ther. 2016 Nov;24(11):1939-1948
pubmed: 27545313
Clin Adv Periodontics. 2019 Sep;9(3):110-114
pubmed: 31490042
Am J Orthod Dentofacial Orthop. 2019 Apr;155(4):584-591
pubmed: 30935613
Gene. 2009 May 15;437(1-2):14-21
pubmed: 19374024
Oncogene. 2007 Oct 15;26(47):6816-28
pubmed: 17934488
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Oncotarget. 2015 Sep 29;6(29):27343-58
pubmed: 26160841
Mol Med Rep. 2017 May;15(5):2991-3000
pubmed: 28358415
EMBO J. 2009 Feb 4;28(3):274-85
pubmed: 19153607
J Biol Chem. 2016 Feb 12;291(7):3439-54
pubmed: 26670608
Biomech Model Mechanobiol. 2013 Apr;12(2):249-65
pubmed: 22539046
Am J Transl Res. 2019 Jun 15;11(6):3398-3411
pubmed: 31312353
Am J Orthod Dentofacial Orthop. 2013 Jul;144(1):4-12
pubmed: 23810038
J Clin Exp Dent. 2012 Dec 01;4(5):e292-6
pubmed: 24455038